0.1188
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Volume | 4,325 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Timber Pharmaceuticals Inc | TMBR | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.1188 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
18 | 4,325 | - | 0.09 - 1.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:35:17 | formt | 200 | $ 0.1188 | USD |
Timber Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 15.74M | 132.45M | 132.26M | $ 295.74k | $ - | -0.26 | -0.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 0.90% |
Timber Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TMBR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1354 | 0.187 | 0.1181 | 0.1437771 | 55,639,551 | -0.0166 | -12.26% |
1 Month | 0.27 | 0.2825 | 0.09 | 0.1245108 | 27,463,045 | -0.1512 | -56.0% |
3 Months | 0.256 | 0.41 | 0.09 | 0.1452434 | 10,965,363 | -0.1372 | -53.59% |
6 Months | 0.3388 | 0.4105 | 0.09 | 0.1611573 | 5,625,692 | -0.22 | -64.94% |
1 Year | 0.98 | 1.05 | 0.09 | 0.2653959 | 3,748,978 | -0.8612 | -87.88% |
3 Years | 4.11 | 4.17 | 0.09 | 1.11 | 3,352,458 | -3.99 | -97.11% |
5 Years | 4.11 | 4.17 | 0.09 | 1.11 | 3,352,458 | -3.99 | -97.11% |
Timber Pharmaceuticals Description
Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist). |